Connect with us

BUSINESS

Novus Acquisiti (OTCMKTS:NDEV) Reports Revenues Of $57,862 In Q4 2019

Published

on

Novus Acquisiti (OTCMKTS:NDEV) has reported robust revenues of $57,862 in Q4 2019. It is an increase of 17.2% when compared to the same period last year. The company has posted revenues of $219,240 in 2019. It represents an increase of 22% when compared to the previous year.

Improves In-network providers

Chief Executive Officer of Novus, Frank Labrozzi, said the company demonstrated continued growth in 2019 and expects to continue the same momentum in 2020. It sees an increase in the commercialization of the Cannabis Health Plan and expects to record phenomenal growth. In nine states, which legalized THC, the company has improved its In-Network providers.

Uninsured Non-Elderly Americans

Novus expects continued growth for its plans from uninsured and non-elderly Americans. It expects a total of 30 million from this segment. Several people in this bracket are uninsured and spend over one-third of the money from their pockets in the whole year. Novus has a presence in states like Illinois, Colorado, Nevada, Arizona, and California in which the uninsured rates 10% or higher. Many people in these states are uninsured because of the cost of health insurance is very high.

Expanding network of THC providers

Novus is expanding its network of THC providers that services its members/ patients in areas offering state-wide and city-wide delivery options. The providers of CBD offer delivery of CBD nationwide.

Signs an MGA agreement with Healthfield Solutions

Novus has announced the signing of an MGA accord with Healthfield Solutions, LLC, to sell its Cannabis Med Plan. Apart from marketing Novus Cannabis Med Plan along with its life, dental and supplemental health plans, Healthfield also trains its 1,600 agents. Its client base is more than 250,000.

Cannabis companies engaged in the cultivation and extraction are under pressure from the shareholders to increase profitability. Novus helps such companies with its tailored health plans say usage-based health plans. The companies can offer discounts/ rebates to the customers using Novus tailored health plans. Therefore, Verticals can offer affordable cannabis meds to their members and improve volumes and maintain higher profits.

Novus offers two plans: 1) offer a higher discount and also increase cannabis list price, 2) a higher markdown, and earn less money on cannabis meds sale. Most of the Verticals select the first plan to improve their margins.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement

BUSINESS

BetterLife Pharma Inc. (OTCMKTS: BETRF) Announces Significant Progress in H1 2021

Published

on

There are reportedly more than 265 million people across the globe suffering from depression. Unfortunately, the only available treatment is psychedelics, which again has its drawbacks, including being expensive and unpredictable side effects. This clearly explains a far-fetched unmet need. However, according to BetterLife Pharma Inc. (OTCMKTS: BETRF), it is possible to treat any neurological condition, including depression and related side effects such as hallucinations. Thanks to several human clinical trials in H1 2021. 

The emerging biotech has provided substantial progress concerning H1 2021. The company scaled up the process development for GMP manufacturing. Additionally, there was an execution of several agreements with leading researchers at marquee institutions for preclinical pharmacology. Other IND-enabling studies included Nova Labs- GLP cardiac studies, Eurofins Discovery – Pharmacology and safety, ITR Labs – GLP bioavailability and toxicology, and Comparative in-vitro studies vs. LSD with the University of California San Diego. 

The Development of TD-0148A for Treatment of Major Depressive Disorders

The projection for depressive and neurological disorders, which include a cluster of headaches, stands at nearly US$25 billion by 2030. However, BetterLife’s TD-0148Aa second-generation lysergic acid diethylamide (“LSD”) derivative molecule is believed to be a possible solution. And with a unique and patented manufacturing process, the company has issued patents on the synthesis of this potential treatment. The good news is that, unlike psychedelics, TD-0148A has the potential to overcome several side effects. Additionally, it does not require the presence of a therapist because it is self-administered. 

The company says it is also working on a second compound, TD-010, and is projected to treat benzodiazepine dependency before developing other neurological-related disorders. 

Meanwhile, it is not long ago since BetterLife Pharma Inc. recruited Mr. Henri Sant-Cassia to its Board of Directors. The co-founder of The Conscious Fund has been a serial entrepreneur since his early twenties before joining the plant medicine field. His experience also spreads out to the manufacturing, retail, and research of cannabinoid-based products. This experience in the psychedelic space will be precious in developing non-hallucinogenic compounds for mental health disorders.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Auxly Cannabis Group Inc. (OTCMKTS: CBWTF) Takes over the Summer Season with a Suite of High-Quality and Unique Cannabis Products

Published

on

More Americans will soon access legal cannabis as more states are expected to advance cannabis legalization measures in the coming years. Some of the keys for unlocking the potential of cannabis include continued innovation and execution excellence while building authentic relationships with consumers. That said, a leading consumer packaged goods company in the cannabis market, Auxly Cannabis Group Inc. (OTCMKTS: CBWTF), has announced a new set of product line-ups for the summer season. 

“Canadians deserve something special after a year and a half of pandemic life, and we wanted to make sure our brands rose to the occasion… developers and marketing experts have leveraged consumer insights this summer to bring a suite of high-quality and unique cannabis products…,” Senior Vice President, Commercial, Auxly Andrew MacMillan acknowledged

Use of Focused Strategies to Grow its Market Share 

Auxly’s involvement in a strategic expansion into the dried flower market is quickly birthing results. The company has been riding on success from the dried flower offerings under its Back Forty brand. Through this brand, Auxly bagged almost 2% of the entire national cannabis flower market in June. The total achievement was a 5.2% share of the national market emanating from the successful sale of dried flowers and the company’s leadership position in cannabis 2.0 products. 

According to the CEO, Hugo Alves, they have built on deep consumer insights and execution excellence. They will also continue introducing a more robust line-up of new products in line with the consumer’s needs. A suite of high-quality and unique cannabis products will take center stage this summer; vapes, edibles, oil, capsules, and concentrates, among others, and they are expected to help the company gain meaningful market share. Kolab Project, Back Forty, Foray, and Dosecann are also some of Auxly’s in-house brands the company is about to launch in the coming weeks.  This will come along with unique edible products but for select provinces.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Rubicon Organics Inc. (OTCMKTS: ROMJF) Outlines its Corporate and Operational Highlights Covering the First Half of 2021

Published

on

Have you ever been in a situation of sickness where you felt utterly helpless? The instituting of Rubicon Organics Inc. was at the height of the lack of high-quality, organic cannabis products for medicinal use. Its founders spent several years perfecting the art of organic cannabis greenhouse cultivation, and before long, the company became a household name. It is one of the only six Organic Certified cannabis producers in Canada with Fraser Valley Organic Producers Association (FVOPA) certification. And over the years, the company has invested in innovative and sustainable practices, from using only organic inputs to minimizing its waste and packaging. 

As the Canadian cannabis market continues to increase, Rubicon Organics is also registering incredible milestones. While unveiling its operational update, the company outlined several milestones, including a 132% increase in the number of new products its Q3, 2021. Additionally, the company’s 1964 Supply Co. premium brand was introduced to New Brunswick in June 2021, listing in seven provinces. As well, five provincial distributors accepted Homestead, a mainstream brand developed for the avid cannabis consumer. 

The Organization’s Corporate Highlights Demonstrating Significant Growth Potential

Rubicon Organics is focused on achieving industry-leading profitability and has a keen eye for innovation and the development of brands. Some of its flagship super-premium brands include Simply Bare Organic with a launch of 10 new SKUs and super-premium concentrate brand LAB THEORY, among others. 

In its first half of 2021, the company launched Wildflower CBD Topicals, a closed organic certified extraction services’ deal with The Valens Company. In addition, it stepped into Yukon territory through a Cannabis Purchase and Sale Pact with Cannabis Yukon for the distribution of its cannabis products. 

In other news, Rubicon Organics announced Cannabis Cultivators of B.C. (CCBC), a non-profit industry association. With the incorporation of Pure Sunfarms and Tantalus Labs, CCBC will work with policymakers to advocate for the growth of a responsible cannabis industry in British Columbia (B.C.). This can be viewed as a timely move given the thriving and fast-growing legal cannabis industry in B.C.            

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories